205 related articles for article (PubMed ID: 25208121)
21. Exploration of novel strategies to enhance monoclonal antibodies targeting.
Khawli LA; Epstein AL
Q J Nucl Med; 1997 Mar; 41(1):25-35. PubMed ID: 9195850
[TBL] [Abstract][Full Text] [Related]
22. Radiolabelled monoclonal antibodies in clinical and surgical oncology: a review.
Biassoni L; D'Andrea V; Biancari F; Santoni F; Dibra A; De Antoni E
Panminerva Med; 1997 Mar; 39(1):46-52. PubMed ID: 9175421
[TBL] [Abstract][Full Text] [Related]
23. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
[TBL] [Abstract][Full Text] [Related]
24. [Immunoscintigraphy using radio-labeled monoclonal antibodies. Development of a method of cancer diagnosis and hopes for a new form of therapy].
Mach JP; Bischof-Delaloye A; Curchod S; Studer A; Grob JP; Volant JC; Mosimann F; Givel JC; Douglas P; Leyvraz S
Schweiz Med Wochenschr; 1987 Jul; 117(29):1076-86. PubMed ID: 3499666
[TBL] [Abstract][Full Text] [Related]
25. Imaging of pancreatic adenocarcinoma with radiolabeled monoclonal antibodies.
Mariani G
Ann Oncol; 1999; 10 Suppl 4():37-40. PubMed ID: 10436782
[TBL] [Abstract][Full Text] [Related]
26. (99m)Tc-labeled murine ior C5 monoclonal antibody in colorectal carcinoma patients: pharmacokinetics, biodistribution, absorbed radiation doses to normal organs and tissues and tumor localization.
Iznaga-Escobar N; Ramos-Suzarte M; Morales-Morales A; Torres-Arocha L; Rodríguez-Mesa N; Pérez-Rodriguez R
Methods Find Exp Clin Pharmacol; 2004 Nov; 26(9):687-96. PubMed ID: 15632954
[TBL] [Abstract][Full Text] [Related]
27. Breast cancer imaging with radiolabeled antibodies.
Goldenberg DM; Nabi HA
Semin Nucl Med; 1999 Jan; 29(1):41-8. PubMed ID: 9990682
[TBL] [Abstract][Full Text] [Related]
28. The feasibility of radioimmunotherapy of head and neck cancer.
Gerretsen M; Quak JJ; Brakenhoff RH; Snow GB; van Dongen GA
Eur J Cancer B Oral Oncol; 1994; 30B(2):82-7. PubMed ID: 8032305
[TBL] [Abstract][Full Text] [Related]
29. Detection of colorectal carcinoma by anti-CEA monoclonal antibody (IOR-CEA1) labeled with 99mTc scintigraphy.
Sirisriro R; Boonkitticharoen V; Kraiphibul P; Ratanatharathorn V; Sumboonnanon K; Kanjanapitak A; Kuhapremma T; Sritara C; Puchinda D; Chouplywech P; Jalayondeja V; Pekanan P; Rochanawutanon M; Intaramarn C; Ayudhya AN; Chokesuwathana P
Hepatogastroenterology; 2000; 47(32):405-13. PubMed ID: 10791201
[TBL] [Abstract][Full Text] [Related]
30. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.
Iznaga-Escobar N; Torres Arocha LA; Morales Morales A; Ramos Suzarte M; Rodríguez Mesa N; Pérez Rodríguez R
J Nucl Med; 1998 Nov; 39(11):1918-27. PubMed ID: 9829584
[TBL] [Abstract][Full Text] [Related]
31. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin.
Torres LA; Perera A; Batista JF; Hernández A; Crombet T; Ramos M; Neninger E; Pérez M; Sánchez EL; Romero S; Aguilar V; Coca MA; Iznaga-Escobar N
Nucl Med Commun; 2005 Dec; 26(12):1049-57. PubMed ID: 16264350
[TBL] [Abstract][Full Text] [Related]
33. 188Re-direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: biodistribution, normal organ dosimetry, and toxicology.
Iznaga-Escobar N
Nucl Med Biol; 1998 Jul; 25(5):441-7. PubMed ID: 9720661
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibodies in solid tumours: approaches to therapy with emphasis on gynaecological cancer.
Fleckenstein G; Osmers R; Puchta J
Med Oncol; 1998 Dec; 15(4):212-21. PubMed ID: 9951683
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
[TBL] [Abstract][Full Text] [Related]
36. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma.
Baum RP; Niesen A; Hertel A; Nancy A; Hess H; Donnerstag B; Sykes TR; Sykes CJ; Suresh MR; Noujaim AA
Cancer; 1994 Feb; 73(3 Suppl):1121-5. PubMed ID: 8306256
[TBL] [Abstract][Full Text] [Related]
37. Radioimmunodetection and radioimmunotherapy of breast cancer.
Riva P; Franceschi G; Gentile R; Riva N; Casi M
Tumori; 1997; 83(2):552-7. PubMed ID: 9226019
[No Abstract] [Full Text] [Related]
38. Preparation and comparative evaluation of 99mTc-labeled 2-iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodies.
Mishra AK; Iznaga-Escobar N; Figueredo R; Jain VK; Dwarakanath BS; Pérez-Rodríguez R; Sharma RK; Mathew TL
Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):653-60. PubMed ID: 12616957
[TBL] [Abstract][Full Text] [Related]
39. Radioimmunodiagnosis and therapy.
Verhaar-Langereis MJ; Zonnenberg BA; de Klerk JM; Blijham GH
Cancer Treat Rev; 2000 Feb; 26(1):3-10. PubMed ID: 10660488
[TBL] [Abstract][Full Text] [Related]
40. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
